ClinicalTrials.gg

Program

trontinemab

Also written as “Trontinemab” and “RO7126209”.

Its studies are mostly in Alzheimer Disease, led by Hoffmann-La Roche.

Furthest: phase 3, since Sep 10, 20255 company-led studies, 4 open or runningNext primary completion: Jul 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche54 open or runningphase 3since Sep 10, 2025Jul 16, 2019Jul 31, 2027phase 2 · NCT04639050
  • Named in Hoffmann-La Roche’s own pipeline as RG6102 trontinemab, phase 3, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2019First study: phase 1 study in Alzheimer DiseaseFirst studyNCT04023994 · 36 enrolled · United States
  2. Nov 17, 2020Phase 2 study in Alzheimer DiseaseNCT04639050 · 241 enrolled · United States, Australia, Canada and more
  3. Sep 10, 20252 phase 3 studies in Alzheimer DiseaseNCT07170150, NCT07169578
  4. Jul 17, 2026Phase 3 study in Alzheimer DiseaseNCT07717411 · 1,600 planned · United States, Argentina, Australia and more

Ahead

  1. Jul 31, 2027Primary completion: phase 2 study in Alzheimer DiseaseNCT04639050
  2. Feb 16, 2028Primary completion: phase 3 study in Alzheimer DiseaseNCT07170150
  3. Feb 16, 2028Primary completion: phase 3 study in Alzheimer DiseaseNCT07169578
  4. Jul 30, 2032Primary completion: phase 3 study in Alzheimer DiseaseNCT07717411

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07717411Alzheimer Disease · United States, Argentina, Australia and more3RecruitingJul 30, 20321,600
NCT07170150Alzheimer Disease · United States, Argentina, Australia and more3Active, not recruitingFeb 16, 20281,060
NCT07169578Alzheimer Disease · United States, Argentina, Brazil and more3Active, not recruitingFeb 16, 20281,101
NCT04639050Alzheimer Disease · United States, Australia, Canada and more2Active, not recruitingJul 31, 2027241
NCT04023994Alzheimer Disease · United States1CompletedJul 17, 202036

How it is read

Names in the registry

  • “Trontinemab”, 3 entries
  • “RO7126209”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.